Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 124 participants.

Also called NCT01237301

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 124 participants (enrolled count) (from the registry)
Sponsor
HealthPartners Institute (from the registry)
Registry
  • NCT NCT01237301
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01237301. Randomized; no masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2014-01-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes
Acronym
REACT3
Intervention (Device)
CGM Group
Intervention (Device)
SMBG Group
Lead sponsor
HealthPartners Institute (class: other)
Collaborator
Roche Diagnostics GmbH (class: industry)
Collaborator
International Diabetes Center at Park Nicollet (class: other)

Record details

Record id
cardio:ct-nct01237301
Content hash
c6ea1b697b14cf3860bb3b8095f77af5cca2ad298ec4495a1b7cb008efda4bce